Mycophenolate Mofetil Sandoz (Mycophenolate Mofetil)

The drug is converted to mycophenolic acid, which selectively blocks the enzyme inosine monophosphate dehydrogenase (IMPDH). This inhibition reduces the synthesis of guanosine nucleot nucleotides, a key building block for lymphocyte proliferation, thereby suppressing T‑ and B‑cell activity and reducing graft rejection.

The exact dose and dosing schedule are determined by the prescribing physician based on the type of transplant, patient weight, renal function and other clinical factors. Patients should follow the individualized regimen provided by their healthcare professional.

Safety in pregnancy and lactation has not been fully established. Women of child‑bearing potential should discuss potential risks with their physician, and effective contraception is generally recommended during treatment. Breastfeeding decisions should also be made in consultation with a healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Compared with calcineurin inhibitors such as cyclosporine or tacrolimus, Mycophenolate Mofetil offers a different mechanism—targeting nucleotide synthesis rather than calcineurin signaling. It is often used in combination with these agents to achieve synergistic immunosuppression while allowing lower doses of each drug, potentially reducing individual side‑effect profiles.

Store the product at ambient temperature, preferably below 25 °C. Keep it in the original packaging to protect from moisture and light. Do not refrigerate or freeze the tablets, and keep them out of reach of children.

Mycophenolate Mofetil Sandoz is taken orally, usually as a tablet, with or without food as directed by the prescriber. The dose may be divided into two administrations per day to maintain stable blood levels, but the exact schedule should follow the physician’s instructions.

Serious risks include opportunistic infections, severe neutropenia or leukopenia, hepatic dysfunction, and rare cases of progressive multifocal leukoencephalopathy (PML). Patients should be monitored regularly for signs of infection, blood‑cell abnormalities and liver enzyme changes.

Patients with known hypersensitivity to mycophenolate mofetil or any component of the formulation should avoid the drug. It is also contraindicated in individuals with uncontrolled severe infections, and caution is advised in those with significant renal or hepatic impairment.